The addition of toripalimab-tpzi (Loqtorzi) to concurrent chemoradiotherapy (CCRT) led to an overall response rate (ORR) of 100% (95% CI, 85.9%-100%) in patients with locally advanced cervical cancer, according to data from a phase 1b trial…
Toripalimab Plus CCRT Generates 100% ORR, But Safety Concerns Warrant Additional Research in Locally Advanced Cervical Cancer
